Immunitybio, Inc. last reported quarterly results on Aug 4, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $51.2 million (+93.9% year over year) and diluted EPS of -$0.22. It usually reports 9–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
51
+93.9%
|
-230
-148.9%
|
-0.22
-120.0%
|
|
Apr 9, 2026
9 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
44
+167.6%
|
-633
-388.1%
|
-0.62
-313.3%
|
|
Jan 15, 2026
15 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
38
+407.0%
|
-62
-4.7%
|
-0.06
+22.3%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
32
+425.1%
|
-67
+21.6%
|
-0.07
+50.0%
|
|
Jul 25, 2025
25 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
26
+2423.9%
|
-93
+31.2%
|
-0.10
+50.0%
|
|
Apr 15, 2025
15 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
17
+41192.5%
|
-130
+3.3%
|
-0.15
+25.0%
|
|
Mar 3, 2025
62 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
8
+5333.1%
|
-59
+74.7%
|
-0.08
+77.0%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
6
+7346.3%
|
-86
+10.3%
|
-0.14
+26.3%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1326110
- Former names
- NantKwest, Inc. (until Mar 8, 2021); Conkwest, Inc. (until Jul 13, 2015); ZelleRx Corp (until Oct 9, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.